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1. Introduction 
The proposal of this chapter is explain the importance and relevance of the understanding of 
the role that play the level in the serum glucose during the acute myocardial infarction 
(AMI). Since many years the investigation in this area has showed that the hyperglycemia is 
a strong predictor of mortality in acute myocardial infarction, as representation of the 
response of the myocardial cell to the ischemic injury, related mainly to acute catecholamine 
release. 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals 
with diabetes, for which 65% of deaths are attributable to heart disease or stroke. 
Hyperglycemia is encountered in up to 50% of all ST elevation myocardial infarcted 
(STEMI) patients, whereas previously diagnosed DM is present in only 20% to 25% of 
STEMI patients.1 When admission glucose level exceeds 200 mg/dL, mortality is similar in 
non-DM and DM subjects with MI. Admission glucose has been identified as a major 
independent predictor of both in-hospital congestive heart failure and mortality in STEMI.2 
In the HEART2D Study treating diabetic survivors of AMI with prandial versus basal 
strategies achieved differences in fasting blood glucose, less-than-expected differences in 
postprandial blood glucose, similar levels of A1C, and no difference in risk for future 
cardiovascular event.3 
Recently the glucose variability has been highlighted. In the results in a re analysis of 
HEART2D study results, the intraday glucose variability as target compared with the basal 
glucose, in diabetic type 2 patients after myocardial infarction, showed similar overall 
glycemic control but did not result in a reduction in cardiovascular outcomes4. Treating 
diabetic survivors of AMI with prandial versus basal strategies achieved differences in 
fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar 
levels of A1C, and no difference in risk for future cardiovascular event. 
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2. Diabetes mellitus and risk for myocardial infarction 
The main cause of death in the industrialized countries is the coronary artery disease (CAD). 
The risk of myocardial infarction is high in patients with diabetes mellitus. In United States, 
diabetes is the most prevalent risk factor for cardiovascular events5 The patient with 
diabetes mellitus have  increased risk for cardiovascular disease, a risk that contributes to a 
significant decrease in  life expectancy. The patients with diabetes have a risk for myocardial 
infarction (MI) comparable to that of the risk of recurrent myocardial infarction in a patient 
without diabetes. The association between diabetes and cardiovascular disease has been 
well identified, and the increased of risk for acute coronary syndromes and the poor 
outcome linked to raised blood glucose levels has been studied in many trials. 
A Finnish population-based study has shown that patients with diabetes without a previous 
MI have as great a risk for infarction as individuals without diabetes with a previous 
myocardial infarction (Figure 1).11 The 7-year incidence rates of MI (fatal and nonfatal) in 
subjects without diabetes were 18.8% in those with a previous MI and 3.5% in those without 
a history of infarction; the corresponding rates in individuals with diabetes were 45.0% and 
20.2%, respectively6 
 
Figure 1. Diabetes mellitus as a risk equivalent of coronary artery disease. 
(Adapted from Hafner S M,N Engl J Med.1998;339:229.342) 
Diabetes mellitus is associated with a 2 to 4 fold increase of the risk for cardiovascular 
disease.7,8  75 to 80% of the deaths in patients with diabetes mellitus are conditioned by a 
thrombotic event5 This increased risk is the main factor underlying the excess mortality and 
reduced life expectancy of people with type 2 diabetes; the life expectancy of people with 
type 2 diabetes at the age of 40 is reduced by an estimated 8 years in comparison with 
individuals without diabetes9 
The prognosis is poorer in patients with diabetes mellitus type 2 that suffers a myocardial 
infarction compared with people without diabetes mellitus. In patients with acute 
myocardial infarction the underlying mechanism in the increase of mortality associated to 
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glucose levels are poor understood. In a study by Nicolau JC and cols, with 52 patients with 
acute myocardial infarction with ST segment elevation and hyperglycemia, in the first 24 
hours compared radionuclide ventriculography at day 4 and six months, finding that basal 
glucose level like independent and powerful predictor of left ventricular growth after an 
acute myocardial infarction10 
Hyperglycemia increases the morbility and mortality in hospitalized patients in Intensive 
Care Units with acute myocardial infarction, stroke and those with aortocoronary bypass. 
The treatment with infusion of insulin has showed a better outcome in these patients11 
A1c hemoglobin (A1cHb) or glycosilated hemoglobin is a marker of the glucose level in two 
previous months, and that is affected in minimal mode by the levels of glucose associated to 
acute coronary syndromes. In the OPTIMAAL study, in Danish population with acute 
myocardial infarction complicated with heart failure, was concluded that A1cHb levels 
showed to be a predictor of mortality in patients without diabetes previously known.12 
In a Japanese study was evaluated the impact of elevated level of glucose in patients with 
acute myocardial infarction with percutaneous coronary intervention, concluding that the 
hyperglycemia  at time of  admission was associated with a increased mortality a short term 
(30 days), and that the presence de diabetes mellitus was associated a poor outcome at long 
term (3 years), considering that both, the acute hyperglycemia in myocardial infarction and 
diabetes mellitus must be treated as two different problems13 
3. Mechanisms induced by hyperglycemia than increased risk in acute 
myocardial infarction 
Acute phase hyperglycaemia and diabetes are both associated with adverse outcomes in 
acute myocardial infarction, with higher reported incidences of congestive heart failure, 
cardiogenic shock, and death. However, the association between hyperglycaemia and 
adverse outcomes is not confined to patients with diabetes. The mechanism is not clear, but 
it is commonly regarded as a response to stress resulting from catecholamine induced 
glycogenolysis. Hyperglycemia, therefore, is seen as an epiphenomenon that is associated 
with poor outcomes only because adrenergic stress is closely related to the extent of 
myocardial injury. 
The possible mechanisms that influence the increased risk in diabetes for cardiovascular 
events include, insulin resistance, changes in endothelial function, dyslipidemia, chronic 
inflammation and release of mediators of inflammation, procoagulability and impaired 
fibrinolysis. 
3.1. Insulin resistance 
Insulin resistance is a hallmark in diabetes mellitus type 2 and obesity, the resistance to 
action of insulin in skeletal muscle, leads to a decrease in the glucose disposal and the use of 
fatty acids and compensatory hyperinsulinemia.14 With relative insulinopenia, however, the 
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ischemic myocardium is forced to use free fatty acids instead of glucose as an energy source 
because myocardial glucose uptake is acutely impaired. Thus, a metabolic crisis may ensue 
as the hypoxic myocardium becomes less energy efficient in the setting of hyperglycemia 
and insulin resistance. 
The SMART study group published a prospective cohort study in 2611 patients with 
manifest arterial disease without known diabetes. Homeostasis model of insulin resistance 
(HOMA-IR) was used to quantify insulin resistance. The relation of HOMA-IR with 
cardiovascular events (vascular death, myocardial infarction or stroke) and all causes of 
mortality were assessed. In patients with manifest arterial disease without known diabetes, 
the results of this trials concludes than insulin resistance increases with the number of 
metabolic syndrome components, and elevated insulin resistance increases the risk of new 
cardiovascular events15 
Diabetes mellitus type 2 is result of two developments, a chronic overnutrition with 
resultant insulin resistance and least a relative failure of pancreatic ß-cells to release 
sufficient insulin to maintain glucose homeostasis. Insulin resistance is the basic mechanism, 
but its diagnosis is not straightforward. Commonly, attempts are made using the 
homeostasis model of insulin resistance16 
Intact pro insulin is a precursor molecule of the insulin that is released into circulation. 
Proinsulin is associated with increased resistance to insulin, and have a similar adipogenetic 
activity than insulin, but only the 10% to 20% of the glucose-lowering effect. Recently, 
determination of proinsulin has been used as a diagnostic tool because an increasing 
proinsulin to insulin ratio predicts insulin resistance and deterioration of glucose tolerance.17 
Hyperglycemia is a reflection of relative insulinopenia, which is associated with increased 
lipolysis and free fatty acid generation, as well as diminished myocardial glucose uptake 
and a decrease in glycolytic substrate for myocardial energy needs in STEMI. Myocardial 
ischemia results in an increased rate of glycogenolysis and glucose uptake via translocation 
of GLUT-4 receptors to the sarcolemma.18 
Finally, in the setting of acute MI and revascularization, blood glucose control in patients 
with diabetes should routinely involve fasting and post meal glucose measurements (such 
as hyperglycemic peaks with the associated sequelae of hyperinsulinemia, reactive oxygen 
species generation, and endothelial dysfunction) because only the latter reflects the amount 
and type of ingested carbohydrates.19-20 
3.2. Endothelial dysfunction 
A single layer of endothelial cells lines the inner surface of all blood vessels, providing a 
metabolically active interface between blood and tissue that modulates blood flow, nutrient 
delivery, coagulation and thrombosis, and leukocyte diapedesis. It synthesizes important 
bioactive substances, including nitric oxide and other reactive oxygen species, 
prostaglandins, endothelin, and angiotensin II, that regulate blood vessel function and 
structure. Nitric oxide potently dilates vessels and mediates much of the endothelium’s 
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control of vascular relaxation. A number of fundamental mechanisms contribute to the 
decreased bioavailability of endothelium-derived nitric oxide in diabetes: 
1. Hyperglycemia inhibits production of nitric oxide by blocking eNOS synthase 
activation and increasing the production of reactive oxygen species, especially 
superoxide anion (O2−), in endothelial and vascular smooth muscle cells. Superoxide 
anion directly quenches nitric oxide by forming the toxic peroxynitrite ion, which 
uncouples eNOS by oxidizing its cofactor, tetrahydrobiopterin, and causes eNOS to 
produce O2 
2. Insulin resistance leads to excess liberation of free fatty acids from adipose tissue, which 
activate the signaling enzyme protein kinase C, inhibit phosphatidylinositol-3 (PI-3) 
kinase (an eNOS agonist pathway), and increase the production of reactive oxygen 
species—mechanisms that directly impair nitric oxide production or decrease its 
bioavailability once produced. 
3. Production of peroxynitrite decreases synthesis of the vasodilatory and antiplatelet 
prostanoid prostacyclin. 
In addition to reducing ambient concentrations of nitric oxide, diabetes increases the 
production of vasoconstrictors, most important, endothelin-1, which activates endothelin-A 
receptors on vascular smooth muscle cell to induce vasoconstriction. 
Acute coronary syndromes are associated to unestable atheromatous plaques in which 
inflammation and endothelial dysfunction play key roles, as well as in subsequent occlusive 
coronary thrombosis a global flow abnormality affecting the entire coronary tree is 
associated with adverse clinical outcomes in patients with ACS and might be caused by a 
combination of global inflammation and vasoconstriction.21-22 
Endothelial dysfunction is caused by acute hyperglycemia. Williams et al assessed 
endothelium-dependent vasodilation through brachial artery infusion of methacholine 
chloride in non-diabetic subjects. They showed that hyperglycemia significantly attenuated 
the forearm blood flow response to methacholine, but did not reduce endothelium-
independent vasodilation to verapamil.23 
3.3. Dyslipidemia 
Characteristic abnormalities in the lipid profile in type 2 diabetes include elevated 
triglyceride levels, decreased atheroprotective high-density lipoprotein (HDL) levels, and 
increased levels of small dense LDL. Increased efflux of free fatty acids from adipose tissue 
and impaired insulin-mediated skeletal muscle uptake of free fatty acids increase hepatic 
free fatty acid concentrations.24 In response, the liver increases VLDL production and 
cholesteryl ester synthesis.25 
Free fatty acids combine with a cholesterol molecule to form a cholesteryl ester. Cholesteryl 
ester concentrations may regulate VLDL production, with increased concentrations 
resulting in elevated VLDL synthesis. Overproduction of triglyceride-rich lipoproteins and 
impaired clearance by lipoprotein lipase lead to the hypertriglyceridemia common in 
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diabetes. Low levels of HDL represent the second common abnormality in type 2 diabetes. 
Elevated levels of triglyceride rich lipoproteins lower HDL levels by promoting exchanges 
of cholesterol from HDL to VLDL via cholesteryl ester transfer protein. Diabetic patients 
with CAD more commonly have the combination of elevated triglycerides and low HDL 
than elevated total and LDL cholesterol levels. 
Strongly related to insulin resistance, obesity is a known risk factor for heart failure. Animal 
studies suggest that the underlying mechanisms are overstorage of lipids and lipotoxic 
injury to myocytes associated with high serum levels of free fatty acid and triglycerides that 
involve increased free fatty acid uptake, diminished mitochondrial oxidative capacity, 
generation of ROS, and increased apoptosis. 
3.4. Inflammation 
In a study Esposito et al26 measured circulating levels of cytokines, including interleukin 
(IL)-6, IL- 18 and tumor necrosis factor-α in subjects with normal or IGT during 3 
consecutive pulses of intravenous glucose separated by a 2-h interval. The plasma cytokine 
levels increased as the blood glucose level increased but immediately returned to normal as 
glucose returned to normal levels. Interestingly, when the first elevation in the blood 
glucose level was maintained by subsequent continuous intravenous glucose infusion, 
plasma cytokine concentrations gradually returned to normal levels. 
The exact mechanism by which glucose stimulates pro inflammatory events is not clear, 
although indirect evidence suggests that it does so possibly by stimulating production of 
tumor necrosis factor (TNF)-α (a pro inflammatory cytokine). A diet with a high glycemic 
load and hyperglycemia induced production of acute-phase reactants. Similar to glucose, 
TNF-α also enhances free radical generation by augmenting polymorphonuclear leukocyte 
NADPH oxidase activity, activates NF-κB, and increases intercellular adhesion molecule-1 
expression in endothelial cells. This similarity in the actions of glucose and TNF-α, and the 
ability of former to enhance acute phase reactants suggests, but does not prove, that glucose 
may enhance TNF-α production and brings about its pro inflammatory actions. 
TNF-α is secreted by adipose tissue, macrophages and cardiac tissue, and plays roles in the 
pathogeneses of insulin resistance, type 2 diabetes mellitus, inflammation, and septic shock. 
Release of TNF-α occurs early in the course of AMI and reduces myocardial contractility in a 
dose dependent manner.27-28 
It has been suggested that four key biochemical changes induced by hyperglycemia: 
increased flux through the polyol pathway (in which glucose is reduced to sorbitol, 
reducing levels of both NADPH and reduced glutathione), increased formation of advanced 
glycation end products,  activation of protein kinase C (with effects ranging from vascular 
occlusion to expression of pro-inflammatory genes), and  increased shunting of excess 
glucose through the hexosamine pathway (mediating increased transcription of genes for 
inflammatory cytokines and plasminogen activator inhibitor-1 [PAI-1]) – are all activated by 
a common mechanism: overproduction of superoxide radicals. Excess plasma glucose drives 
 
Hyperglycemia and Diabetes in Myocardial Infarction 175 
excess production of electron donors (mainly NADH/H+) from the tricarboxylic acid cycle; 
in turn, this surfeit results in the transfer of single electrons (instead of the usual electron 
pairs) to oxygen, producing superoxide radicals and other reactive oxygen species (instead 
of the usual end product, H2O). The superoxide anion itself inhibits the key glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GADPH), and in consequence, 
glucose and glycolytic intermediates spill into the polyol and hexosamine pathways, as well 
as additional pathways that culminate in protein kinase C activation and intracellular AGE 
formation.29 (Figure 2) 
 
Figure 2. Potential mechanism by which hyperglycemia-induced mitochondrial superoxide overproduction 
activates four pathways of hyperglycemic damage. Excess superoxide partially inhibits the glycolytic enzyme 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), thereby diverting upstream metabolites from 
glycolysis into pathways of glucose overutilization. This results in increased flux of dihydroxyacetone 
phosphate (DHAP) to diacylglycerol (DAG), an activator of protein kinase C (PKC), and of triose phosphates 
to methylglyoxal, the main intracellular AGE precursor. Increased flux of fructose-6-phosphate (Fructose-6-P) 
to UDP-N-acetylglucosamine increases modification of proteins by O-linked N-acetylglucosamine(GIcNAc), 
and increased glucose flux through the polyol pathway consumes NADPH and depletes glutathione. GFAT, 
glutamine: fructose-6-phosphate aminotransferase; Gln, glutamine; Glu, glutamate; NAD, nicotinamide 
dinucleotide; UDP, uridine diphosphate. Adapted from Ceriello A. Diabetes care 2009 Nov;32 Suppl 2:S232-6 
3.5. Procoagulability 
Hyperglycemia also stimulates coagulation and platelet aggregation. It has been reported 
that hyperglycemia elevates coagulant activation markers, including thrombin antithrombin 
complexes and soluble tissue factor, whereas hyperinsulinemia inhibits fibrinolysis. 
Platelets can modulate vascular function and participate significantly in thrombus 
formation. Abnormalities in platelet function may exacerbate the progression of 
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atherosclerosis and the consequences of plaque rupture. Intraplatelet glucose concentration 
mirrors the extracellular concentration, since glucose entry into the platelet does not depend 
on insulin. In the platelet, as in endothelial cells, elevated glucose levels lead to activation of 
protein kinase C, decreased production of platelet-derived nitric oxide, and increased 
formation of O2− 
Patients with diabetes have increased platelet-surface expression of glycoprotein Ib (GpIb), 
which mediates binding to von Willebrand factor, and GpIIb/IIIa, which mediates platelet 
fibrin interaction. These abnormalities may result from decreased endothelial production of 
the anti aggregants nitric oxide and prostacyclin, increased production of fibrinogen, and 
increased production of platelet activators, such as thrombin and von Willebrand factor. 
Thus, diabetic abnormalities increase intrinsic platelet activation and decrease endogenous 
inhibitors of platelet activity  
3.6. Impaired fibrinolysis 
Patients with type 2 diabetes have impaired fibrinolytic capacity because of elevated levels 
of plasminogen activator inhibitor type 1 in atherosclerotic lesions and in non atheromatous 
arteries.30 Diabetes increases the expression of tissue factor, a potent procoagulant, and 
plasma coagulation factors such as factor VII and decreases levels of endogenous 
anticoagulants such antithrombin III and protein C.31-32 
Impaired fibrinolysis, due to elevated levels of plasminogen activator inhibitor type 1 (PAI-
1), further contributes to a hypercoagulable state in patients with diabetes. PAI-1 inhibits the 
conversion of plasminogen into plasmin and consequently reduces fibrinolytic activity. An 
in vivo study in healthy volunteers using a hyperinsulinemic euglycemic clamp, 
demonstrated a 2.5-fold increase in levels of PAI-1 relative to baseline. This study suggested 
that impaired fibrinolysis in patients with diabetes is mediated by hyperinsulinemia rather 
than hyperglycemia.33 
Hyperinsulinemia increases PAI-1 levels by stabilization of the PAI-1 messenger RNA 
transcript through the actions of insulin and insulin-like growth factor type 1. Adipocytes 
have been found to be a major source of PAI-1, providing a direct link between obesity and 
a suppressed fibrinolytic system. Finally, inflammatory cytokines such as transforming 
growth factor-beta and tumor necrosis factor-alpha  both of which are believed to have 
important roles in the metabolic syndrome  increase the release of PAI-1 from adipose tissue 
4. The hyperglycemic effect in the outcomes in acute coronary syndromes 
Acute hyperglycemia is associated with multiple biological effects that contribute to a poor 
outcome of the acute coronary syndromes, 34 this effects are listed in the table number 1 
Admission hyperglycemia is associated with long-term risk for ACS mortality35 ,but this 
association is not homogeneous in different ACS presentations,36 unstable angina, NSTEMI, or 
STEMI. Besides, mortality up to 1 year can be predicted both by admission glucose and fasting 
blood glucose, but the better predictor of mortality for longer periods is fasting glucose.37 
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In the OASIS registry, a 6-nation study of unstable angina and non–Q-wave MI, diabetes 
independently increased the risk of death by 57%.38 Elevated plasma glucose and glycated 
hemoglobin levels on admission are independent prognosticators of both in-hospital and 
long-term outcome regardless of diabetic status.39-40 For every 18 mg/dL increase in glucose 
level, there is a 4% increase in mortality in nondiabetic subjects.41 
Hyperglycemia also interferes with ischemic preconditioning. Ischemic preconditioning is a 
potent endogenous cardioprotective mechanism that is promoted by the brief transient 
ischemia proceeding subsequent prolonged ischemia and reperfusion. In the clinical setting, 
it has been demonstrated that prodromal angina occurring shortly before the onset of AMI 
is associated with smaller infarct size, preserved LV function and lower mortality after 
reperfusion therapy.42 
 
Figure 3. In the absence of acute hyperglycemia, prodromal angina was associated with preserved 
predischarge in left ventricular ejection fraction (LVEF). Among patients with acute hyperglycemia, 
there was no significant difference in predischarge LVEF between patients with (blue bars) and without 
prodromal angina (red bars). Adapted from Ishihara et al Ischemic preconditioning delays infarct 
progression during the early hours after the onset of AMI and extends the window of time for 
reperfusion therapy43 
 
Endothelial dysfunction 
Platelet hyperreactivity 
Increased cytokine activation 
Increased lipolysis and free fatty acid levels 
Reduced glycolysis and glucose oxidation 
Increased oxidative stress (Increased myocardial apoptosis) 
Impaired microcirculatory function (“no-reflow” phenomenon) 
Impaired ischemic preconditioning 
Impaired insulin secretion and insulin stimulated glucose uptake 
Table 1. Acute Cardiovascular Effects of Hyperglycemia 
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5. Importance of glucose levels in diabetic and nondiabetic patients in 
acute myocardial infarction. 
Elevation of blood glucose on admission is a common feature during the early phase after 
acute myocardial infarction, even in the absence of a history of diabetes mellitus.44 However 
the optimal plasma glucose level may be different between diabetic and nondiabetic 
patients. Many studies have shown that an elevated plasma glucose level on admission is a 
major independent predictor of in-hospital and long-term outcome in patients with acute 
myocardial infarction, regardless of diabetes status. 
Acute hyperglycemia is common in patients with STEMI even in the absence of a history of 
diabetes. Hyperglycemia is encountered in up to 50% of all STEMI patients, whereas 
previously diagnosed diabetes mellitus is present in only 20% to 25% of STEMI patients. The 
prevalence of type 2 diabetes mellitus or impaired glucose tolerance may be as high as 65% 
in myocardial infarction patients without prior diabetes when oral glucose tolerance testing 
is performed.  
High blood glucose concentration may increase risk of death and poor outcome after acute 
myocardial infarction. Capes SE et al did a systematic review and meta-analysis to assess the 
risk of in-hospital mortality or congestive heart failure after myocardial infarction in patients 
with and without diabetes who had stress hyperglycemia on admission. Concluding that acute 
hyperglycemia with myocardial infarction is associated with an increased risk of in-hospital 
mortality in patients with and without diabetes; the risk of congestive heart failure or 
cardiogenic shock is also increased in patients without diabetes (Figure 4) 
 
Figure 4. Stress hyperglycemia in acute MI and relative risk of mortality in nondiabetic patients 
Acute hyperglycemia is common among patients with acute myocardial infarction. The 
prevalence of acute hyperglycemia in prior studies varies from <10% to >80%.45-46 It mostly 
depends on the definition of acute hyperglycemia, which is differs from study to study. 
Threshold glucose concentration used to define acute hyperglycemia has ranged from 6.1 
mmol/L (1 mmol/L=18 mg/dl) to 11.0 mmol/L. There is a linear correlation between the 
blood glucose level on admission and mortality after acute myocardial infarction. Therefore, 
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there is no clear cut-off value of blood glucose to predict mortality and no consensus about 
the appropriate definition of acute hyperglycemia for patients with myocardial infarction. In 
most of the recent studies, 10.0 mmol/L or 11.0 mmol/L of blood glucose on admission is 
used to define acute hyperglycemia.  
Diabetes has been a consistently powerful risk factor for development of post infarction 
heart failure, accounting for 66% of mortality during the first year. The combination of 
diabetes and HF after MI requires preventive action because it is usually not associated with 
the characteristic left ventricular remodeling. If left ventricular remodeling does develop, it 
requires appropriate treatment that includes revascularization and metabolically and 
hemodynamically effective treatment strategies that limit infarct size, cardiac dysfunction, 
and left ventricle remodeling 
In patients without a history of diabetes, there was a linear relation between admission 
blood glucose level and in-hospital mortality (Figure 5) 
 
Figure 5. Relationship between admission blood glucose level and in-hospital mortality. It is near-linear 
in patients without diabetes (blue) but U-shaped in patients with diabetes (red). Adapted from Ishihara 
M, et al. Am J Cardiol 2009; 104: 769-74 
In the presence of hyperglycemia, proteins and lipids are irreversibly glycated by non-
enzymatic mechanisms, and these advanced glycated end products accumulate in the cells 
and extracellular space of blood vessels, enhancing atherogenic processes. A cell surface 
receptor for this glycated end products (a “RAGE”) has been isolated; binding of AGEs and 
other pro inflammatory ligands to this signal-transducing receptor has a multitude of 
effects, including increased smooth muscle cell proliferation, migration and activation of 
mononuclear phagocytes, induction of cytokines such as TNF-α, and in endothelial cells, 
increased vascular permeability, oxidative stress, vasoconstriction and expression of 
adhesion molecules. Glucotoxic effects involve three additional mechanisms for dysfunction 
in the diabetic heart. These involve: 
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1. Reactive oxygen species that amplify hyperglycemia induced activation of protein 
kinase C isoforms. 
2. Increased formation of glucose derived advanced glycation end products 
3. Increased glucose flux through the aldose reductase pathways  
Admission glucose levels have a prognostic role in patients with acute myocardial infarction 
and in patients with heart failure.47-48 
In a Spanish study, the findings highlight a 2-fold increase in mortality risk with 
hyperglycemia after STEMI, as an additive to clinical parameters. Moreover, it is of interest 
to note that the probability of mortality was not modified when DM was added in the 
model, indicating that the predictive influence of DM was marginal.49 Similar results were 
found by Pinto et al.50 in a subgroup of patients in CLARITY-TIMI 28 study trial. In 1027 
patients with STEMI treated with PCI, with 26% incidence of DM. 
6. The effect of hyperglycemia and diabetes in outcomes for 
thrombolysis, arrhythmias and left ventricle function 
In patients with acute STEMI, thrombolysis in myocardial infarction (TIMI) frame counts 
may show significant variability despite presence of grade 3 TIMI flow after successful 
reperfusion and lower TIMI frame counts after reperfusion are associated with more 
favorable prognosis. No data are present regarding TIMI frame counts and admission 
glucose values in non-diabetic patients with acute ST elevation MI who undergo successful 
primary percutaneous coronary intervention. In STEMI subjects, acute hyperglycemia is 
associated with reduced TIMI grade 3 flow before intervention compared with normal 
glucose blood levels and is the most important predictor of the absence of coronary 
perfusion.51 Similarly, diabetic subjects have reduced myocardial blush grades and 
diminished ST-segment resolution after successful coronary intervention in STEMI, 
consistent with diminished microvascular perfusion.52 Acute hyperglycemia also is 
associated with impaired microcirculatory function as manifest by “no reflow” phenomenon 
on myocardial contrast echocardiography after percutaneous coronary intervention.53 
Elevated admission glucose levels are associated with increased risk of life-threatening 
complications, especially arrhythmias in diabetic and non-diabetic AMI patients. This 
increased risk of complications is one of the possible explanations for the elevated in-hospital 
mortality in AMI patients presenting with hyperglycemia. In a clinical study by Dziewierz et 
al54 admission hyperglycemia was associated with increased risk of ventricular 
tachycardia/ventricular fibrillation, atrial fibrillation, second to third atriventricular block, 
pulmonary edema. A analysis from the Krakow Registry of Acute Coronary Syndromes 
database, found that diabetes mellitus and presence of chest pain on admission, as well as 
heart rate and systolic blood pressure on admission, were independent predictors of new onset 
of atrial fibrillation55 
In a Spanish study with the aim to evaluate the impact of glucose levels on admission and 
high risk ventricular tachyarrhythmia in hospital mortality in patients with acute myocardial 
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infarction, the admission glucose levels >180 mg/dL had a significantly increased risk in in-
hospital only high risk ventricular tachyarrhythmia only in patients without diabetes56 
Several mechanisms promote metabolic consequences that lead to cardiac dysfunction and 
heart failure in diabetes. An important mechanism deduced mainly from experimental work 
is myocardial energy demand/supply mismatch from increased oxygen demand in the 
diabetic myocardium related to increased vascular stiffness; and decreased energy supply 
from myocardial underperfusion. 
The CARISMA study enrolled patients with a recent MI and LV systolic dysfunction. The 
patients were implanted with an implantable loop recorder and followed for 2 years 
allowing continuous monitoring and diagnosis of asymptomatic and symptomatic 
arrhythmias.57 Diastolic dysfunction in post myocardium infarcted patients with moderate-
to-severe left ventricle systolic dysfunction predisposes to cardiovascular ischemic events 
such as re-infarction and stroke. New-onset atrial fibrillation also occurs more frequently in 
patients with diastolic dysfunction. Re-infarction and stroke were more frequent in patients 
with new onset atrial fibrillation, but the increased risk of ischemic events was independent 
of development of atrial fibrillation, suggesting that diastolic dysfunction in infarcted 
patients by itself is an important risk factor for ischemic events.58 
Diabetes is associated with a higher risk of death or heart failure hospitalization across the 
spectrum of left ventricle ejected fraction (LVEF) in high-risk post-myocardial infarction 
patients. The magnitude of reduction in risk of death or heart failure hospitalization 
associated with increasing LVEF is significantly attenuated among patients with diabetes 
when compared to patients without diabetes59 
VALIANT was a randomized, double-blind trial of the efficacy and safety of Valsartan 
versus Captopril versus combination therapy following MI complicated by clinical or 
radiological signs of heart failure, evidence of left ventricle systolic dysfunction (LVEF ≤ 
35% by echocardiography or ≤40% by radionuclide ventriculography), or both60 
7. Glucose variability in acute myocardial infarction 
Hyperglycemia is a strong predictor of mortality in patients hospitalized with acute 
myocardial infarction. Professional society guidelines have accordingly advised glucose 
control in hyperglycemic patients. These same guidelines also recommend avoiding 
hypoglycemia, even though the association between hypoglycemia and adverse outcomes in 
acute myocardial infarction patients is controversial. In a meta-analysis of   OASIS-6 and 
CREATE-ECLA studies Goyal A. et al conclude that both admission and post admission 
hyperglycemia predict 30-day death in acute myocardial infarction patients. In contrast, 
only hypoglycemia on admission predicted death, and this relationship dissipated after 
admission. These data suggest hypoglycemia may not be a direct mediator of adverse 
outcomes in myocardial infarction61 
Short-term variation in blood glucose levels is a daily challenge for patients with diabetes. It 
confers a possible increased risk for hypoglycemia, and it has been suggested that glucose 
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variability is related to cardiovascular risk 62–64. However, reanalysis of the Diabetes Control 
and Complications Trial (DCCT) and DCCT/Epidemiology of Diabetes Interventions and 
Complications (EDIC) dataset examining the predictive value of glucose variability on 
microvascular and neurologic complications did not show an effect of glucose variability 
independent from mean glucose and HbA1c, and randomized controlled trials  specifically 
targeting glucose variability are lacking 
Oscillating hyperglycemia also induces apoptosis of cells. Risso et al reported that 
intermittent high glucose enhanced apoptosis of human endothelial cells that were 
incubated in media containing different glucose concentrations.65 Apoptosis, which was 
studied by viability assay, cell cycle analysis, DNA fragmentation, and morphological 
analysis, was enhanced in human umbilical vein endothelial cells exposed to intermittent, 
rather than constant, high glucose concentrations. 
They are secondary to deterioration in microvascular function causing a decrease in 
myocardial blood flow. In diabetic patients without microvascular or macrovascular 
complications, postprandial myocardial perfusion defects may represent an early marker of 
the atherogenic process in the coronary circulation; hence, its reversal constitutes a potential 
goal of treatment66. (Figure 6) 
 
Figure 6. Changes in myocardial perfusion indexes after overnight fasting (baseline) and 120 minutes 
after standard mixed meal ingestion (postprandial) in type 2 diabetic patients (blue bars) and control 
subjects (red bars). Adapted from Scognamiglio R et al. Circulation 2005;112:179-84. 
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The American Heart Association Diabetes Committee of the Council on Nutrition, Physical 
Activity, and Metabolism prepared a scientific statement summarizing the current 
understanding of the association between elevated glucose and patient outcomes in acute 
coronary syndromes and identifying major knowledge gaps that remain for further 
investigation efforts. 
The committee assessed data from the Diabetes Mellitus Insulin-Glucose Infusion in Acute 
Myocardial Infarction (DIGAMI), Hyperglycemia: Intensive Insulin Infusion In Infarction 
(HI-5), Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction 
Treatment and Evaluation-Estudios Clinicos Latino America (CREATE-ECLA), and other 
clinical trials in ACS patients with hyperglycemia. 
Most cardiovascular disease risk factors make similar contributions to risk among patients 
with and without diabetes, and the relationship between fasting plasma glucose or HbA1C 
levels and macrovascular complications among diabetic patients is not strong. For example, 
the United Kingdom Prospective Diabetes Study Group (UKPDS) study found that 
“intensive” control of fasting blood glucose  among diabetic patients reduced the relative risk 
for myocardial infarction  by only 16% as compared to conventional, diet-based therapy 
(p=0.052).67 What, then, accounts for the greatly increased cardiovascular risk among patients 
with diabetes? Postprandial hyperglycemia, which captures “spikes” in blood glucose levels 
that may not be fully reflected in fasting blood glucose or glycosylated hemoglobin  levels67, 
has historically been overlooked as a CV risk factor among diabetic patients, those with 
isolated impaired glucose tolerance  and those in the general population. 
8. Treatment of acute hyperglycemia in acute myocardial infarction 
Many clinicians caring for diabetic patients have a “fasting glucocentric” outlook: they focus 
on fasting blood glucose and HbA1C levels as the main measures of glycemic status when 
evaluating a diabetic patient’s cardiovascular risk. However, there is broad epidemiological 
evidence that just as acute hyperglycemia portends a poorer clinical outcome among 
critically ill patients, postprandial hyperglycemia predicts cardiovascular disease and 
mortality not only among patients already identified as diabetic, but also among subjects in 
the general population. Mounting mechanistic evidence suggests that acute hyperglycemia 
has myriad adverse effects that are mediated through oxidative stress. Moreover, some 
available interventional studies suggest that strategies directed toward decreasing 
postprandial glucose in outpatients and acute hyperglycemia during hospitalizations for 
cardiovascular events may improve clinical outcomes. Postprandial hyperglycemia 
determines myocardial perfusion defects in type 2 diabetic patients.  
The concept of a metabolic cocktail (GIK) to stabilize cell membranes through potassium 
influx, promote glucose oxidation, and reduce free fatty acid accumulation to protect the 
ischemic myocardium dates back to the work of Sodi-Pallares et al.68 However, the CREATE-
ECLA study showed no benefit of GIK in a large number of STEMI subjects, dampening the 
enthusiasm for aggressive use of a metabolic cocktail in STEMI69 
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The Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm 
Regulation (NICE-SUGAR) study70 randomly assigned 6,104 patients admitted to the 
intensive care unit to undergo either intensive glucose control, with a target blood glucose 
range of 4.5–6.0 mmol/L or conventional glucose control, with a target of ≤10.0 mmol/L. The 
90-day mortality was significantly higher in the intensive control group than in the 
conventional-control group (27.5%vs. 24.9%, P=0.02). The difference in mortality between 
the 2 treatment groups was still significant after adjustment for the predefined baseline risk 
factors (adjusted odds ratio, 1.14; 95% confidence interval 1.01–1.29; P=0.04). Severe 
hypoglycemia (defined as a blood glucose level ≤2.2 mmol/L) was recorded more frequently 
in the intensive-control group. After these studies, recent guidelines revised their 
recommendation from intensive glucose control to mild glucose control, avoiding 
hypoglycemia. 
Due as an emerging risk factor for cardiovascular disease, acute hyperglycemia during 
cardiovascular events may be considered analogous to postprandial hyperglycemia and 
may carry with it similar adverse clinical implications. Accordingly, several groups, 
including the American Diabetes Association71 and the American Heart Association72, have 
encouraged more rigorous control of blood glucose levels during acute hospitalizations for 
cardiovascular diseases. The clinical trial basis for these recommendations is not yet 
exceedingly robust. 
Although sustained chronic hyperglycemia produces excessive protein glycation, acute 
fluctuations of glucose may activate oxidative stress and contribute to endothelial 
dysfunction, which may also participate in the development of diabetes complications. 
Therefore, reducing postprandial hyperglycemia and glucose variability are now 
recognized as a priority in treatment of type 2 diabetes. Therapeutic agents acting on 
postprandial glucose excursions are of particular interest to diminish glucose variability. 
Emerging therapeutic agents such as the glucagon-like peptide 1 agonists and the 
dipeptidyl peptidase (DPP)-4 inhibitors are very attractive. Both increase insulin secretion 
and suppress glucagon release in response to meals, in a glucose-dependent manner. This 
review will focus on the increasing impact of postprandial hyperglycemia and glycemic 
variability in developing diabetes complications and the role of DPP-4 inhibitors 
(sitagliptin, vildagliptin, saxagliptin) in reducing both defects presenting in people with 
type 2 diabetes.74 
In the more recent DIGAMI-2 study (n= 1253 patients), however, mortality did not differ 
significantly between diabetic patients randomized to either acute insulin infusion followed 
by insulin-based long-term glucose control, insulin infusion followed by standard glucose 
control, or standard management, probably reflecting a lack of difference in glucose control 
among the three groups75 
Because hyperglycemia remained one of the most important predictors of outcome in acute 
coronary syndromes, however, it appears to be reasonable to keep glucose levels within 
normal ranges in diabetic patients. Target glucose levels between 90 and 140 mg/dL (5 and 
7.8 mmol/L) have been suggested. Care needs to be taken to avoid blood glucose levels 
 
Hyperglycemia and Diabetes in Myocardial Infarction 185 
below 80–90 mg/dL (4.4–5 mmol/L), however, as hypoglycemia-induced ischemia might 
also affect outcome in diabetic patients with acute coronary syndromes76 
The HI-5 study77 attempted to rectify some of the issues that were encountered in DIGAMI-2 It 
was the first randomized clinical trial of intensive insulin infusion that included 
hyperglycemic acute myocardial infarcted patients without previously established diabetes. 
Patients assigned to the intensive insulin-infusion arm received standard insulin and dextrose 
infusion that was then adjusted to maintain glucose levels between 72 and 180 mg/dL. Patients 
in the conventional arm received their baseline diabetes medications (including subcutaneous 
insulin); additional short-acting subcutaneous insulin was permitted for those with a glucose 
level >288 mg/dL. There was no difference in mortality rates among the groups during 
hospitalization or at 3 or 6 months. There were, however, statistically and clinically significant 
reductions in post–myocardial infarction heart failure during hospitalization (10% absolute 
risk reduction) and in re infarction at 3 months (3.7% absolute risk reduction). 
9. Conclusions and recommendations 
Concluding, there is currently insufficient evidence to consider glucose control as a quality 
measure during acute myocardial infarction hospitalization, although this position may 
change in the future. The recommendations from a scientific statement from the American 
Heart Association, in hyperglycemia in acute coronary syndromes78, are the next: 
1. Glucose level should be a part of the initial laboratory evaluation in all patients with 
suspected or confirmed acute coronary syndrome. 
2. In patients admitted to an ICU with acute myocardial infarction, glucose levels should 
be monitored closely. It is reasonable to consider intensive glucose control in patients 
with significant hyperglycemia (plasma glucose >180 mg/dL), regardless of prior 
diabetes history. Although efforts to optimize glucose control may also be considered in 
patients with milder degrees of hyperglycemia, the data regarding a benefit from this 
approach are not yet definitive, and regardless of diabetes status. The precise goal of 
treatment has not yet been defined. Until further data are available, approximation of 
normoglycemia appears to be a reasonable goal (suggested range for plasma glucose 90 
to 140 mg/dL), as long as hypoglycemia is avoided.  
3. Insulin, administered as an intravenous infusion, is currently the most effective method 
of controlling glucose among patients hospitalized in the ICU. Effective protocols for 
insulin infusion and glucose monitoring have been developed in other patient 
populations. Care should be taken to avoid hypoglycemia, which has been shown to 
have an adverse prognostic impact. 
4. Treatment should be instituted as soon as feasible, without compromising the 
administration of life-saving and evidence-based treatments. 
5. In patients hospitalized in the non-ICU setting, efforts should be directed at 
maintaining plasma glucose levels >180 mg/dL with subcutaneous insulin regimens. 
6. Acute myocardial infarcted patients with hyperglycemia but without prior history of 
diabetes should have further evaluation (preferably before hospital discharge) to 
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determine the severity of their metabolic derangements. This evaluation may include 
fasting glucose and HbA1C assessment and, in some cases, a post discharge oral 
glucose tolerance test. 
7. Before discharge, plans for optimal outpatient glucose control should be determined in 
those patients with established diabetes, newly diagnosed diabetes, or evidence of 
insulin resistance. 
The chronic and acute hyperglycemia associated to acute coronary syndromes, mainly in 
acute myocardial infarction is an independent and determinant factor in the outcome for 
patients with and without diabetes mellitus. The evidence in clinical trials has showed the 
importance of admission glucose and glycated hemoglobin, in the evolution, risk for 
complications, and therapeutic response of patients with acute myocardial infarction.  The 
control of blood glucose levels in patients with acute myocardial infarction, will lead to 
better outcomes regardless of diabetes status. The precise goal of treatment has not yet been 
defined. Until further data are available, approximation of normoglycemia appears to be a 
reasonable goal, as long as hypoglycemia is avoided. 
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